Get started
GT Biopharma, Inc.GT Biopharma, Inc.GT Biopharma, Inc.

GT Biopharma, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

GTBP chart


Full chart

GTBP upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪6.75 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−7.48 USD
Net income (FY)
‪−7.60 M‬ USD
Revenue (FY)
0.00 USD
Shares float
‪1.96 M‬
Beta (1Y)
1.50

Employees


Employees (FY)
2
Change (1Y)
0
Revenue / Employee (1Y)
0.00 USD
Net income / Employee (1Y)
‪−3.80 M‬ USD

About GT Biopharma, Inc.


Sector
Health Technology
CEO
Michael Breen
Headquarters
San Francisco
Website
gtbiopharma.com
Founded
1965
FIGI
BBG000DHJ738
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of the immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The TriKE platform is designed to harness and enhance the cancer killing abilities of a patient's immune system natural killer cells (NK cells). Its product, GTB-3550, is initially developed for the treatment of AML and MDS, and other CD33+ hematologic cancers. GT Biopharma has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology. The company was founded in 1965 and is headquartered in San Francisco, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

GTBP news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of GTBP is 2.99 USD — it has decreased by −8.28% in the past 24 hours. Watch GT Biopharma, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange GT Biopharma, Inc. stocks are traded under the ticker GTBP.
GTBP stock has fallen by −14.51% compared to the previous week, the month change is a −3.15% fall, over the last year GT Biopharma, Inc. has showed a −61.22% decrease.
GTBP reached its all-time high on Mar 28, 2016 with the price of 146,818.04 USD, and its all-time low was 1.72 USD and was reached on Dec 20, 2024. View more price dynamics on GTBP chart.
See other stocks reaching their highest and lowest prices.
GTBP stock is 20.98% volatile and has beta coefficient of 1.50. Track GT Biopharma, Inc. stock price on the chart and check out the list of the most volatile stocks — is GT Biopharma, Inc. there?
Today GT Biopharma, Inc. has the market capitalization of ‪6.75 M‬, it has increased by 56.10% over the last week.
Yes, you can track GT Biopharma, Inc. financials in yearly and quarterly reports right on TradingView.
GT Biopharma, Inc. is going to release the next earnings report on Mar 26, 2025. Keep track of upcoming events with our Earnings Calendar.
GTBP earnings for the last quarter are −1.53 USD per share, whereas the estimation was −2.70 USD resulting in a 43.33% surprise. The estimated earnings for the next quarter are −1.55 USD per share. See more details about GT Biopharma, Inc. earnings.
GTBP net income for the last quarter is ‪−3.41 M‬ USD, while the quarter before that showed ‪−3.71 M‬ USD of net income which accounts for 8.06% change. Track more GT Biopharma, Inc. financial stats to get the full picture.
No, GTBP doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 30, 2024, the company has 2.00 employees. See our rating of the largest employees — is GT Biopharma, Inc. on this list?
Like other stocks, GTBP shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade GT Biopharma, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So GT Biopharma, Inc. technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating GT Biopharma, Inc. stock shows the neutral signal. See more of GT Biopharma, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.